{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:50:40Z","timestamp":1794379840717,"version":"4.9.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["107500"],"award-info":[{"award-number":["107500"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Adoptive cell therapy (ACT) is a rapidly evolving field. Patient-reported outcomes (PROs) allow patients to report the impact of treatment on their quality of life during and after treatment. The systematic review aims to characterise the breadth of PROs utilised in ACT cancer care and provide guidance for the use of PROs in this patient population in the future.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search was conducted (MEDLINE, PsycINFO, Embase and CINAHL) in August 2021 by two reviewers. Search terms covered the following: \u201cadoptive cell therapy\u201d, \u201cpatient-reported outcomes\u201d and \u201ccancer\u201d. Studies were included if they used a PRO measure to report the impact of ACT. The methodological quality of PROs was assessed. Forward and backward reference searching was conducted of any relevant papers. A quality grading scale was applied based on Cochrane and Revenson criteria for classification of high-quality studies. Key data from the studies and the included PROs was extracted by two researchers and tabulated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One-hundred nine papers were identified; 11 papers were included. The majority of studies were single-arm trials or observational studies. Twenty-two different PROs were identified; none was ACT specific. The PROMIS-29 and EQ-5D were most commonly used. Few studies collected PRO data in the first 1\u20132\u00a0weeks. Four studies followed patients up for over a year, and a further four studies followed patients for approximately 3\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>None of the PROs identified have been designed specifically for ACT. Appropriateness of existing instruments should be considered. It should be considered whether it is appropriate to collect data more frequently in the acute stage and then less frequently during follow-up. It should be considered if one tool is suitable at all time points or if the tool should be adapted depending on time since treatment. More research is needed to identify the exact timings of PRO assessments, and qualitative work with patients is needed to determine the most important issues for them throughout the treatment and follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-023-02337-8","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T11:02:18Z","timestamp":1696071738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9026-1789","authenticated-orcid":false,"given":"Sally","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Coomber-Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Yorke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"2337_CR1","unstructured":"CAR T cells: engineering immune cells to treat cancer - NCI. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells. [cited 2023 Jul 24]."},{"issue":"1","key":"2337_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56\u201371.","journal-title":"Immunol Rev"},{"key":"2337_CR3","unstructured":"The Association of the British Pharmaceutical Industry. Cell and gene therapy market data. 2016."},{"key":"2337_CR4","unstructured":"Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape."},{"key":"2337_CR5","unstructured":"Adoptive Cell Transfer Therapy - Melanoma Research Alliance.\u00a0"},{"key":"2337_CR6","unstructured":"CAR T-cell therapy and its side effects.\u00a0"},{"issue":"5","key":"2337_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bjh.18335","volume":"198","author":"L Shargian","year":"2022","unstructured":"Shargian L, Raanani P, Yeshurun M, Gafter-Gvili A, Gurion R. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: a systematic review and meta-analysis. Br J Haematol. 2022;198(5):838\u201346.","journal-title":"Br J Haematol"},{"issue":"12","key":"2337_CR8","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/s41375-019-0615-5","volume":"33","author":"M Mohty","year":"2019","unstructured":"Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia. 2019;33(12):2767\u201378.","journal-title":"Leukemia"},{"issue":"3","key":"2337_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","volume":"27","author":"R Chakraborty","year":"2021","unstructured":"Chakraborty R, Hill BT, Majeed A, Majhail NS. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transplant Cell Ther. 2021;27(3):222\u20139.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2337_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"1","key":"2337_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26(1):26\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2337_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.bbmt.2019.10.020","volume":"26","author":"NM Hossain","year":"2020","unstructured":"Hossain NM, Nishimura MI. Late events after CD-19 CAR-T treatment. Biol Blood Marrow Transplant. 2020;26(1):e1-2.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"39","key":"2337_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet. 2019;39(39):433\u201344.","journal-title":"Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet"},{"issue":"4","key":"2337_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2337_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","volume":"21","author":"PG Kluetz","year":"2018","unstructured":"Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, et al. Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute Workshop. Value Health. 2018;21(6):742\u20137.","journal-title":"Value Health"},{"issue":"1","key":"2337_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-020-00219-4","volume":"4","author":"S Cruz Rivera","year":"2020","unstructured":"Cruz Rivera S, McMullan C, Jones L, Kyte D, Slade A, Calvert M. The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders. J Patient-Reported Outcomes. 2020;4(1):1\u201314.","journal-title":"J Patient-Reported Outcomes"},{"issue":"1","key":"2337_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41591-021-01648-4","volume":"28","author":"A Retzer","year":"2022","unstructured":"Retzer A, Aiyegbusi OL, Rowe A, Newsome PN, Douglas-Pugh J, Khan S, et al. The value of patient-reported outcomes in early-phase clinical trials. Nat Me. 2022;28(1):18\u201320.","journal-title":"Nat Me"},{"issue":"5","key":"2337_CR18","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","volume":"19","author":"PG Kluetz","year":"2018","unstructured":"Kluetz PG, O\u2019Connor DJ, Soltys K. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol. 2018;19(5):e267-74.","journal-title":"Lancet Oncol"},{"key":"2337_CR19","unstructured":"FDA. Core patient-reported outcomes in cancer clinical trials | FDA."},{"key":"2337_CR20","unstructured":"FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making | FDA."},{"key":"2337_CR21","unstructured":"FDA. Patient-reported outcome measures: use in medical product development to support labeling claims | FDA. 2009."},{"key":"2337_CR22","unstructured":"Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP) Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man The use of patient-reported outcome (PRO) measures in oncology studies. 2016."},{"key":"2337_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2021.100304","volume":"30","author":"AJN Raymakers","year":"2021","unstructured":"Raymakers AJN, Regier DA, Peacock SJ, Freeman CL. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials. J Cancer Policy. 2021;30: 100304.","journal-title":"J Cancer Policy"},{"key":"2337_CR24","doi-asserted-by":"crossref","unstructured":"Messina AJ, Andrianov V, Mazzolenis D, Vidal-Fisher L. Emerging trends and utilization of patient-reported outcomes (PROs) in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. 2020 May;38(15_suppl):e19142\u2013e19142.","DOI":"10.1200\/JCO.2020.38.15_suppl.e19142"},{"key":"2337_CR25","doi-asserted-by":"crossref","unstructured":"Messina AJ, Andrianov V, Mazzolenis D, Vidal-Fisher L. Emerging trends and utilization of patient-reported outcomes (PROs) in clinical trials of chimeric antigen receptor (CAR) T-cell therapies. 2020 May 25;38(15_suppl):e19142\u2013e19142.","DOI":"10.1200\/JCO.2020.38.15_suppl.e19142"},{"issue":"8","key":"2337_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s10198-021-01337-6","volume":"22","author":"KK Shah","year":"2021","unstructured":"Shah KK, Bennett B, Lenny A, Longworth L, Brazier JE, Oppe M, et al. Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. Eur J Health Econ. 2021;22(8):1301\u20139.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"2337_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/FDDE8516","volume":"10","author":"G Velikova","year":"2022","unstructured":"Velikova G, Absolom K, Hewison J, Holch P, Warrington L, Avery K, et al. Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs. Program Grants Appl Res. 2022;10(1):1\u2013110.","journal-title":"Program Grants Appl Res"},{"issue":"5","key":"2337_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/ACM.0000000000003122","volume":"95","author":"E Teisberg","year":"2020","unstructured":"Teisberg E, Wallace S, O\u2019Hara S. Defining and implementing value-based health care: a strategic framework. Acad Med. 2020;95(5):682\u20135.","journal-title":"Acad Med"},{"key":"2337_CR29","unstructured":"Cheng Kayla Scippa Frederick Locke Julia Thornton Snider Heather Jim RL. Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with Car T-cell therapy: A Qualitative Study."},{"key":"2337_CR30","doi-asserted-by":"publisher","first-page":"100303","DOI":"10.1016\/j.jcpo.2021.100303","volume":"30","author":"K Jenei","year":"2021","unstructured":"Jenei K, Burgess M, Peacock S, Raymakers AJN. Experiences and perspectives of individuals accessing CAR-T cell therapy: a qualitative analysis of online Reddit discussions. J Cancer Policy. 2021;30:100303.","journal-title":"J Cancer Policy"},{"issue":"6","key":"2337_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2021.151216","volume":"37","author":"MS Whisenant","year":"2021","unstructured":"Whisenant MS, Srour SA, Williams LA, Subbiah I, Griffin D, Ponce D, et al. The Unique symptom burden of patients receiving CAR T-cell therapy. Semin Oncol Nurs. 2021;37(6): 151216.","journal-title":"Semin Oncol Nurs"},{"key":"2337_CR32","doi-asserted-by":"crossref","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1).\u00a0","DOI":"10.1186\/s13643-016-0384-4"},{"issue":"5","key":"2337_CR33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147\u201357.","journal-title":"Qual Life Res"},{"key":"2337_CR34","unstructured":"Higgins JP, Altman DG, Sterne JA, Wiley J. Chapter 8: Assessing risk of bias in included studies. 2017;"},{"key":"2337_CR35","doi-asserted-by":"crossref","unstructured":"Revenson TA, Temple LK, McClelland SI. Improving sexual function in female cancer survivors: a systematic review of psychosocial interventions. 2010;28(15_suppl):e19522\u2013e19522.","DOI":"10.1200\/jco.2010.28.15_suppl.e19522"},{"issue":"6","key":"2337_CR36","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1002\/cam4.3664","volume":"10","author":"AI Hoogland","year":"2021","unstructured":"Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, et al. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021;10(6):1936\u201343.","journal-title":"Cancer Med"},{"issue":"Supplement 1","key":"2337_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2020-141703","volume":"136","author":"JM Knight","year":"2020","unstructured":"Knight JM, Arapi I, Szabo A, Yim S, Sauber G, Hillard C, et al. Quality of life, tryptophan metabolites, and neurotoxicity assessments of patients with relapsed or refractory B cell malignancies undergoing CAR 20\/19 - T cell therapy. Blood. 2020;136(Supplement 1):42\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2337_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-136368","volume":"136","author":"T Martin","year":"2020","unstructured":"Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, et al. Health-related quality of life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for relapsed\/refractory multiple myeloma. Blood. 2020;136(Supplement 1):41\u20132.","journal-title":"Blood"},{"issue":"1","key":"2337_CR39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood-2019-121715","volume":"134","author":"S Sidana","year":"2019","unstructured":"Sidana S, Thanarajasingam G, Griffin J, Thompson CA, Burtis M, Warsame R, et al. Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: longitudinal patient reported adverse events, cognition and quality of life. Blood. 2019;134(1):794\u2013794.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2337_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-134646","volume":"136","author":"E Mullane","year":"2020","unstructured":"Mullane E, Jones T, Voutsinas J, Wu QV, Loggers E, Fann J, et al. Patient-reported outcomes at time of CAR-T cell therapy. Blood. 2020;136(Supplement 1):35\u20136.","journal-title":"Blood"},{"key":"2337_CR41","doi-asserted-by":"crossref","unstructured":"Ruark J, Mullane E, Cleary N, Cordeiro A, Bezerra ED, Wu V, et al. HHS Public Access. 2021;26(1):34\u201343.","DOI":"10.1016\/j.bbmt.2019.09.037"},{"issue":"11","key":"2337_CR42","doi-asserted-by":"publisher","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","volume":"27","author":"XS Wang","year":"2021","unstructured":"Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, et al. Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplant Cell Ther. 2021;27(11):930.e1-930.e10.","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"2337_CR43","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","volume":"20","author":"TW Laetsch","year":"2019","unstructured":"Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019;20(12):1710\u20138.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2337_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","volume":"4","author":"RT Maziarz","year":"2020","unstructured":"Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629\u201337.","journal-title":"Blood Adv"},{"issue":"3","key":"2337_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-016-1939-x","volume":"66","author":"H Li","year":"2017","unstructured":"Li H, Huang L, Liu L, Wang X, Zhang Z, Yue D, et al. Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. Cancer Immunol Immunother. 2017;66(3):299\u2013308.","journal-title":"Cancer Immunol Immunother"},{"key":"2337_CR46","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1200\/CCI.21.00023","volume":"5","author":"R Banerjee","year":"2021","unstructured":"Banerjee R, Shah N, Dicker AP. Next-generation implementation of chimeric antigen receptor T-cell therapy using Digital Health. JCO Clin Cancer Inform. 2021;5:668\u201378.","journal-title":"JCO Clin Cancer Inform"},{"key":"2337_CR47","doi-asserted-by":"publisher","unstructured":"Shah N, et al. Secondary quality-of-life domains in patients with relapsed and refractory multiple Myeloma treated with the Bcma-Directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel; bb2121): results from the Karmma clinical trial. Blood. 2020;136(1):28\u20139. https:\/\/doi.org\/10.1182\/BLOOD-2020-136665.","DOI":"10.1182\/BLOOD-2020-136665"},{"issue":"7","key":"2337_CR48","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11136-018-1842-3","volume":"27","author":"RD Hays","year":"2018","unstructured":"Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS \u00ae-29 v2.0 Profile Physical and Mental Health Summary Scores HHS Public Access. Qual Life Res. 2018;27(7):1885\u201391.","journal-title":"Qual Life Res"},{"issue":"3","key":"2337_CR49","first-page":"155","volume":"78","author":"G Balestroni","year":"2012","unstructured":"Balestroni G, Bertolotti G. EuroQol-5D (EQ-5D): an instrument for measuring quality of life. Monaldi Arch Chest Dis. 2012;78(3):155\u20139.","journal-title":"Monaldi Arch Chest Dis"},{"issue":"6846","key":"2337_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones NMB, O\u2019Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ Br Med J. 1992;305(6846):160.","journal-title":"BMJ Br Med J"},{"issue":"8","key":"2337_CR51","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051\u20139.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2337_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1037\/1040-3590.19.3.253","volume":"19","author":"D Watson","year":"2007","unstructured":"Watson D, O\u2019Hara MW, Simms LJ, Kotov R, Chmielewski M, McDade-Montez EA, et al. Development and validation of the Inventory of Depression and Anxiety Symptoms (IDAS). Psychol Assess. 2007;19(3):253\u201368.","journal-title":"Psychol Assess"},{"issue":"2","key":"2337_CR53","first-page":"129","volume":"23","author":"C Cleeland","year":"1994","unstructured":"Cleeland C, Ryan K. Pain assessment: global use of the Brief Pain Inventory - PubMed. Ann Acad Med Singapore. 1994;23(2):129\u201338.","journal-title":"Ann Acad Med Singapore"},{"issue":"2","key":"2337_CR54","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193\u2013213.","journal-title":"Psychiatry Res"},{"issue":"5","key":"2337_CR55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Ins. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Ins"},{"issue":"10","key":"2337_CR56","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"5","key":"2337_CR57","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, De Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"issue":"6","key":"2337_CR58","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","volume":"19","author":"N Wille","year":"2010","unstructured":"Wille N, Badia X, Bonsel G, Burstr\u00f6m K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875\u201386.","journal-title":"Qual Life Res"},{"issue":"7","key":"2337_CR59","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","volume":"18","author":"RD Hays","year":"2009","unstructured":"Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the Patient-Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res. 2009;18(7):873\u201380.","journal-title":"Qual Life Res"},{"issue":"7","key":"2337_CR60","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Shelley Wang X, Chou C, Margaret Harle RT, Marilyn Morrissey R, et al. Assessing symptom distress in cancer patients. Cancer. 2000;89(7):1634\u201346.","journal-title":"Cancer"},{"key":"2337_CR61","doi-asserted-by":"crossref","unstructured":"Alderfer MA, Marsac ML. Pediatric Quality of Life Inventory (PedsQL). Encycl Behav Med. 2013;1448\u20139.\u00a0","DOI":"10.1007\/978-1-4419-1005-9_974"},{"key":"2337_CR62","doi-asserted-by":"crossref","unstructured":"Cella D, Tulsky D, Gray G, Sarafian B, \u2026 ELJC, 1993 undefined. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. researchgate.net. 1993.","DOI":"10.1200\/JCO.1993.11.3.570"},{"issue":"3","key":"2337_CR63","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","volume":"21","author":"RC Gershon","year":"2012","unstructured":"Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21(3):475\u201386.","journal-title":"Qual Life Res"},{"issue":"2013","key":"2337_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/147176","volume":"20","author":"FJ Hlubocky","year":"2013","unstructured":"Hlubocky FJ, Webster K, Cashy J, Beaumont J, Cella D. The development and validation of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma: the Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym). Lymphoma. 2013;20(2013):1\u20139.","journal-title":"Lymphoma"},{"issue":"6","key":"2337_CR65","doi-asserted-by":"publisher","first-page":"151216","DOI":"10.1016\/j.soncn.2021.151216","volume":"37","author":"MS Whisenant","year":"2021","unstructured":"Whisenant MS, Srour SA, Williams LA, Subbiah I, Griffin D, Ponce D, et al. The unique symptom burden of patients receiving CAR T-cell therapy. Semin Oncol Nurs. 2021;37(6):151216.","journal-title":"Semin Oncol Nurs"},{"issue":"7","key":"2337_CR66","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-011-0031-4","volume":"21","author":"TM Atkinson","year":"2012","unstructured":"Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159\u201364.","journal-title":"Qual Life Res"},{"issue":"5","key":"2337_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","volume":"13","author":"M Di Maio","year":"2016","unstructured":"Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016;13(5):319\u201325.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2337_CR68","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: a new era for cancer treatment (review). Oncol Rep. 2019;42(6):2183\u201395.","journal-title":"Oncol Rep"},{"issue":"5","key":"2337_CR69","doi-asserted-by":"publisher","first-page":"390.e1","DOI":"10.1016\/j.jtct.2021.01.003","volume":"27","author":"M Kamal","year":"2021","unstructured":"Kamal M, Joseph J, Greenbaum U, Hicklen R, Kebriaei P, Srour SA, et al. Patient-reported outcomes for cancer patients with hematological malignancies undergoing chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2021;27(5):390.e1-390.e7.","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2337_CR70","first-page":"1120","volume":"28","author":"M Calvert","year":"2022","unstructured":"Calvert M, Cruz Rivera S, Retzer A, Hughes S, Campbell L, Molony-Oates B, et al. Patient reported outcome assessment must be inclusive and equitable. Nature. 2022;28(6):1120\u20134.","journal-title":"Nature"},{"key":"2337_CR71","first-page":"61","volume":"6","author":"T Weldring","year":"2013","unstructured":"Weldring T, Smith SMS. Patient-reported outcomes (pROs) and patient-reported outcome measures (pROMs). Health Serv Insights. 2013;6:61\u20138.","journal-title":"Health Serv Insights"},{"issue":"6","key":"2337_CR72","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s43441-020-00184-6","volume":"54","author":"L Lasiter","year":"2020","unstructured":"Lasiter L, Campbell A, Basch E, Hudgens S, Stewart M, Wu JJ, et al. Use of patient-reported outcomes to understand & measure the patient experience of novel cell and gene therapies. Ther Innov Regul Sci. 2020;54(6):1566\u201375.","journal-title":"Ther Innov Regul Sci"},{"issue":"5","key":"2337_CR73","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","volume":"25","author":"R Chakraborty","year":"2019","unstructured":"Chakraborty R, Sidana S, Shah GL, Scordo M, Hamilton BK, Majhail NS. Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities. Biol Blood Marrow Transplant. 2019;25(5):e155\u201362.","journal-title":"Biol Blood Marrow Transplant"}],"updated-by":[{"DOI":"10.1186\/s13643-024-02540-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000}}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-023-02337-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-023-02337-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T15:13:05Z","timestamp":1714576385000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-023-02337-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2337"],"URL":"https:\/\/doi.org\/10.1186\/s13643-023-02337-8","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13643-024-02540-1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13643-024-02540-1","URL":"https:\/\/doi.org\/10.1186\/s13643-024-02540-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M. C. is a National Institute for Health Research (NIHR) Senior Investigator and receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, UKRI, Macmillan Cancer Support, UCB Pharma, Gilead, Janssen and GSK. M. C. has received personal fees from Astellas, Aparito Ltd., CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Collaboration (ARC), West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd., Janssen Pharmaceuticals, Inc., GSK and Sarcoma UK. OLA declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck outside the submitted work. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or UKRI. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}